Insider Selling: REGENXBIO (NASDAQ:RGNX) CEO Sells $76,468.72 in Stock

REGENXBIO Inc. (NASDAQ:RGNX) CEO Curran Simpson sold 7,624 shares of the company’s stock in a transaction dated Monday, September 29th. The stock was sold at an average price of $10.03, for a total value of $76,468.72. Following the sale, the chief executive officer owned 236,973 shares of the company’s stock, valued at $2,376,839.19. This represents a 3.12% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Curran Simpson also recently made the following trade(s):

• On Wednesday, September 10th, Curran Simpson sold 7,734 shares of REGENXBIO stock. The stock was sold at an average price of $10.02, for a total value of $77,494.68.

REGENXBIO Price Performance

Shares of NASDAQ:RGNX opened at $10.43 on Friday. The firm has a market capitalization of $526.86 million, a PE ratio of -3.03 and a beta of 1.17. The business has a 50-day moving average of $8.99 and a two-hundred day moving average of $8.56. REGENXBIO Inc. has a 12 month low of $5.03 and a 12 month high of $12.22.

REGENXBIO (NASDAQ:RGNX) last announced its quarterly earnings results on Thursday, August 7th. The biotechnology company reported ($1.38) EPS for the quarter, missing the consensus estimate of ($1.13) by ($0.25). REGENXBIO had a negative return on equity of 66.95% and a negative net margin of 112.70%.The firm had revenue of $21.36 million for the quarter, compared to analyst estimates of $40.87 million. As a group, research analysts anticipate that REGENXBIO Inc. will post -4.84 earnings per share for the current year.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. FNY Investment Advisers LLC bought a new position in REGENXBIO during the 1st quarter worth approximately $35,000. Brooklyn Investment Group lifted its holdings in REGENXBIO by 163.7% during the 1st quarter. Brooklyn Investment Group now owns 5,583 shares of the biotechnology company’s stock worth $40,000 after buying an additional 3,466 shares during the last quarter. Steward Partners Investment Advisory LLC lifted its holdings in REGENXBIO by 754.1% during the 2nd quarter. Steward Partners Investment Advisory LLC now owns 5,663 shares of the biotechnology company’s stock worth $46,000 after buying an additional 5,000 shares during the last quarter. Pallas Capital Advisors LLC bought a new position in REGENXBIO during the 1st quarter worth approximately $74,000. Finally, Captrust Financial Advisors bought a new position in REGENXBIO during the 2nd quarter worth approximately $85,000. Institutional investors own 88.08% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on RGNX. Wall Street Zen lowered REGENXBIO from a “hold” rating to a “strong sell” rating in a research note on Saturday, August 9th. Barclays lowered their target price on REGENXBIO from $50.00 to $37.00 and set an “overweight” rating for the company in a research note on Friday, August 8th. HC Wainwright reiterated a “buy” rating and issued a $34.00 target price on shares of REGENXBIO in a research note on Monday, September 8th. Chardan Capital reiterated a “buy” rating and issued a $52.00 target price on shares of REGENXBIO in a research note on Monday, September 8th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of REGENXBIO in a research note on Saturday, September 27th. Five analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, REGENXBIO currently has a consensus rating of “Moderate Buy” and a consensus target price of $28.38.

About REGENXBIO

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.